Summary
Campylobacter jejuni is a major pathogen responsible for a significant number of reported campylobacteriosis cases in the European Union. Due to underdiagnosed and underreported cases, there are no existing studies on this pathogen. Fluoroquinolones have been the primary treatment for campylobacteriosis for many years. Fluoroquinolone resistance is causing an increase, which means that a new class of antibiotics must be introduced. The treatment of campylobacteriosis is currently based on macrolides, but with the increasing rates of resistance, active surveillance for antibiotic resistance is required. The aim of this study was to track the increasing prevalence of AMR in clinical isolates of C. jejuni across Bulgaria for a period of 10 years.